In the last few years, while the potential applications of ctDNA in colon and prostate cancers have been subjects of a steadily-increasing number of investigations, the clinical usefulness of liquid biopsy in the mBC setting has not, so far, been intensively investigated, and much less in the era of CDK4/6i. Here, CDK4 is linked to prostate cancer.